• Appcharge

  Participated · Series B · Aug 2025

  Appcharge is a direct-to-consumer (DTC) platform for mobile game publishers, offering fully branded web stores, gamified offers, global payments checkout, and mobile in-app payments SDKs. The company has launched an iOS Payments SDK, AppDirect, and widely-adopted Payment Links to expand its suite of compliant, scalable DTC tools. Appcharge powers stores for more than 100 games and for over one-third of the top-grossing mobile games, with publishers reporting average profit lifts of 35% and improved retention. The platform is processing more than $500 million in transactions and has grown 14x year-over-year. Appcharge plans to use new funding to scale its platform with new products to meet global industry demand and to lead the next era of customer engagement beyond app stores. The company is headquartered in Tel Aviv and is led by veterans from Rovio, Huge Games, Moon Active, and Play Studios. Appcharge builds a headless commerce platform for game publishers to sell in-game currencies and virtual goods directly to players. The platform links gaming accounts to publisher-run stores, provides pricing and purchasing analytics, and acts as merchant of record by creating local merchant entities, tax registration, payment facilities and fraud prevention. The company processes roughly $200 million annually in purchases and counts customers in the "tens." Founded in 2022 by Maor Sason and based in Tel Aviv, Appcharge plans to expand its analytics with more machine-learning capabilities in the coming months. It positions itself as a complement to app-store and direct storefront efforts rather than an in-app bridge, relying on channels like newsletters and gaming communities for traffic. The funding will support expansion of the product and go-to-market efforts.

• Theranica

  Participated · Series C · Aug 2022

  Theranica is a prescribed digital therapeutics company based in Netanya, Israel and Montclair, NJ that develops advanced neuromodulation devices for migraine and other idiopathic pain conditions. Its flagship product, Nerivio, is an FDA-cleared, prescribed, smartphone-controlled, drug-free wearable worn on the upper arm to treat episodic and chronic migraine in people aged 12 and older. Nerivio utilizes remote electrical neuromodulation to trigger conditioned pain modulation and alleviate migraine headache and associated symptoms. The device is eligible for insurance coverage, can be prescribed by any certified U.S. healthcare provider, and is shipped to patients’ homes through several specialty pharmacies. Theranica intends to use the Series C proceeds to expand its commercial activity in the U.S. Leadership includes CEO Alon Ironi and Chairman and Co-Founder Dr. Shimon Eckhouse. Theranica develops Nerivio Migra, a novel remote neuromodulation device for acute treatment of migraine. The device is currently under review by the FDA and is labeled as an investigational device limited to investigational use in the United States. In October 2018 the company completed a pivotal study across 12 clinical sites in the US and Israel with almost 300 migraine patients; the study met its primary endpoint with high statistical significance and demonstrated high efficacy, safety and tolerability. Founded in 2016, Theranica plans to use new funding to mass-produce Nerivio Migra and, once cleared by the FDA, to deliver the device to millions of migraine patients in the USA. The company positions itself in the electroceuticals space targeting prevalent neurological conditions. Theranica Bio-Electronics develops advanced electroceuticals — drug-free solutions that combine electronics and wireless communication technologies with recent neurology research. Its product line starts with a device for the acute treatment of migraine. The company intends to use Series A proceeds to complete regulatory approval of its first migraine product and to bring that product to mass production. Theranica closed a $6M Series A in 2017. The company was established in 2016 and is based in Netanya, Israel. Founders include Alon Ironi, Ronen Jashek, Slava Barabash and Dr. Shimon Eckhouse. Theranica Bio-Electronics is a Netanya, Israel–based medical device company led by CEO and co-founder Alon Ironi. The company combines neuromodulation therapy with wireless technology to produce proprietary wearable solutions. Its therapeutic 'smart' patches contain a proprietary chip that delivers electrical pulses to neuro-modulate sensory nerves beneath the skin and are controlled by a smartphone app for personalized, portable care. The first commercial application, Nerivio Migra, is a non-invasive, disposable wearable patch used at migraine onset to provide pain relief and often eliminate pain. The company closed a seed financing round for an undisclosed amount. Backers included a group of angel investors led by Dr. Shimon Eckhouse, who will serve as Chairman. The company also assembled a medical advisory board with leading headache and pain experts.

• CathWorks

  Participated · Series B · Oct 2017

  CathWorks applies advanced computational science to elevate coronary angiography from visual assessment to an objective FFR-based decision tool with its FFRangio System. The FFRangio System delivers objective FFR guidance intra-procedurally across the full coronary tree without adding clinical risk or per-procedure costs. The platform is non-invasive and was benchmarked against conventional invasive FFR in the FAST-FFR clinical study. CathWorks received FDA 510(k) clearance on December 19, 2018, using invasive FFR as the predicate for substantial equivalence. The company plans to accelerate clinical and commercial activities and pursue market entry for FFRangio in the United States. Leadership says the technology offers significant clinical and economic benefits for clinicians, patients, and payors. CathWorks develops digital healthcare products for the cardiovascular market, focusing on a real-time platform that determines fractional flow reserve (FFR) in the catheterization laboratory in under five minutes using standard angiographic images. Its lead product reconstructs the coronary tree in three dimensions from standard angiograms and provides clinicians with a complete FFR analysis in all visible coronary arteries simultaneously using proprietary algorithms. The company received a CE Mark on its lead product earlier in the year. CathWorks intends to use newly raised funds to conduct a global pivotal trial to support 510(k) FDA approval. Founded in 2013 and led by CEO Guy Lavi, the company is based in Kfar Saba, Israel.

No current team members are available.